Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schwarz Pharma Inc.

Division of UCB Group
www.schwarzusa.com

Latest From Schwarz Pharma Inc.

Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes

Pfizer’s litigation department scored several key victories in the past year, which the company chalks up to its business approach to running cases and the teamwork of its law firms.

BioPharmaceutical Legal Issues

FDA Generic Labeling Rule Could Help Pfizer In Reglan Product Liability Suit

Alabama Supreme Court is reconsidering its decision holding brand-name manufacturers liable for injuries caused by generics; Pfizer argues that FDA’s forthcoming proposed rule would eliminate concerns that no company could be held liable for injuries from a generic.

BioPharmaceutical United States

KV Settles DoJ Complaint Over Claims For Unapproved Drugs; Two Dozen Companies Sued

The $17 million settlement resolves a False Claims Act suit alleging KV’s Ethex subsidiary illegally received reimbursement for two unapproved drugs; at least three other companies have previously settled with the government.

BioPharmaceutical Regulation

FDA's Next-Generation Review Process: Avoiding the "Crisis Mentality"

There are changes coming to FDA's drug review process that, over the long term, should make the system more predictable and increase the chances for a first-cycle approval. Until then, expect a less forgiving agency when it comes to incomplete submissions-and challenges that may threaten the sanctity of priority reviews.
Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • UCB Group
  • Senior Management
  • Klaus Veitinger, Pres.
    Ron Stratton, VP, Corp. Dev.
    Rich Losiniecki, VP, Finance
  • Contact Info
  • Schwarz Pharma Inc.
    Phone: (262) 238-5704
    6140 W. Executive Dr.
    P.O. Box 2038 Mequon, WI 53092
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register